Patents by Inventor Grant McNaughton-Smith
Grant McNaughton-Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150175585Abstract: A compound having the formula (I): for use in treating a disease; a composition comprising said fused quinonic compound of formula (I) and at least one pharmaceutically acceptable carrier; as well as a method of modulating a Janus Kinase-Signal Transduction and Activators of Transcription (JAK-STAT) pathway. The activation of a JAK and/or STAT pathways are associated with several disease states such as immunological and inflammatory diseases, hyperproliferative disorders including cancer, and myeloproliferative diseases.Type: ApplicationFiled: July 23, 2013Publication date: June 25, 2015Applicant: CENTRO ATLANTICO DEL MEDICAMENTO S.A (CEAMED S.A.)Inventors: Grant McNaughton Smith, Ana Estévez Braun, Sandra Jiménez Alonso, Ángel Domingo Gutiérrez Ravelo, Leandro Fernández Pérez, Bonifacio Nicolás Díaz Chico
-
Publication number: 20100190746Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.Type: ApplicationFiled: November 20, 2009Publication date: July 29, 2010Applicant: ICAGEN, INC.Inventors: Grant A. McNaughton-Smith, James B. Thomas, JR., George S. Amato
-
Publication number: 20080058319Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.Type: ApplicationFiled: April 26, 2007Publication date: March 6, 2008Applicant: Icagen, Inc.Inventors: Grant McNaughton-Smith, George Amato, James Thomas
-
Patent number: 7205307Abstract: The present invention provides a genus of pyrimidine amides that are useful as openers of potassium ion channels. The compounds of the invention are of use in both therapeutic and diagnostic methods.Type: GrantFiled: November 27, 2002Date of Patent: April 17, 2007Assignee: Icagen, Inc.Inventors: Grant A. McNaughton-Smith, George S. Amato, Paul C. Fritch
-
Publication number: 20070004784Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfonamides, and compositions and methods utilizing sulfonamides that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.Type: ApplicationFiled: September 7, 2006Publication date: January 4, 2007Applicant: Icagen, Inc.Inventors: Grant McNaughton-Smith, Aimee Reed, Robert Atkinson
-
Patent number: 7119112Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfonamides, and compositions and methods utilizing sulfonamides that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.Type: GrantFiled: August 14, 2003Date of Patent: October 10, 2006Assignee: ICAgen, Inc.Inventors: Grant A. McNaughton-Smith, Aimee D. Reed, Robert N. Atkinson
-
Publication number: 20060094721Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfonamides, and compositions and methods utilizing sulfonamides that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.Type: ApplicationFiled: August 14, 2003Publication date: May 4, 2006Applicant: Icagen, Inc.Inventors: Grant McNaughton-Smith, Aimee Reed, Robert Atkinson
-
Patent number: 6989398Abstract: Benzanilides are provided which are voltage-dependent potassium channel openers. Methods of using the benzanilides of the invention are also provided.Type: GrantFiled: February 2, 2004Date of Patent: January 24, 2006Assignee: ICAgen, Inc.Inventors: Grant A. McNaughton-Smith, Michael F. Gross, Alan D. Wickenden
-
Publication number: 20050267032Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfone-containing prodrugs, and compositions and methods utilizing sulfone-containing prodrugs that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.Type: ApplicationFiled: May 23, 2005Publication date: December 1, 2005Applicant: Icagen, Inc.Inventors: Alan Fulp, Grant McNaughton-Smith, Aimee Reed, Xiadong Wang
-
Publication number: 20050059823Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.Type: ApplicationFiled: September 10, 2004Publication date: March 17, 2005Applicant: Icagen, Inc.Inventors: Grant McNaughton-Smith, George Amato, James Thomas
-
Publication number: 20040198724Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.Type: ApplicationFiled: December 23, 2003Publication date: October 7, 2004Applicant: ICAgen, Inc.Inventors: Grant A. McNaughton-Smith, James B. Thomas, George S. Amato
-
Publication number: 20040157829Abstract: Benzanilides are provided which are voltage-dependent potassium channel openers. Methods of using the benzanilides of the invention are also provided.Type: ApplicationFiled: February 2, 2004Publication date: August 12, 2004Applicant: ICAgen, Inc.Inventors: Grant A. McNaughton-Smith, Michael F. Gross, Alan D. Wickenden
-
Publication number: 20040106613Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfonamides, and compositions and methods utilizing sulfonamides that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.Type: ApplicationFiled: August 14, 2003Publication date: June 3, 2004Applicant: Icagen, Inc.Inventors: Grant A. McNaughton-Smith, Aimee D. Reed, Robert N. Atkinson
-
Patent number: 6737422Abstract: Benzanilides are provided which are voltage-dependent potassium channel openers. Methods of using the benzanilides of the invention are also provided.Type: GrantFiled: November 1, 2001Date of Patent: May 18, 2004Assignee: ICAgen, Inc.Inventors: Grant A. McNaughton-Smith, Michael F. Gross, Alan D. Wickenden
-
Publication number: 20040029771Abstract: This invention relates to the use of compounds able to decrease potassium ion flow through intermediate conductance calcium activated potassium channels for treatment of diseases related to increased intraocular pressure modulated by intermediate conductance calcium activated potassium channels.Type: ApplicationFiled: February 28, 2003Publication date: February 12, 2004Applicant: Icagen, Inc.Inventors: Gregory C. Rigdon, Jonathan W. Stocker, Grant A. McNaughton-Smith
-
Publication number: 20030181465Abstract: The present invention provides a genus of pyrimidine amides that are useful as openers of potassium ion channels. The compounds of the invention are of use in both therapeutic and diagnostic methods.Type: ApplicationFiled: November 27, 2002Publication date: September 25, 2003Applicant: Icagen, Inc.Inventors: Grant A. McNaughton-Smith, George S. Amato, Paul C. Fritch
-
Patent number: 6605725Abstract: Benzanilides are provided which are voltage-dependent potassium channel openers. Methods of using the benzanilides of the invention are also provided.Type: GrantFiled: November 2, 2001Date of Patent: August 12, 2003Assignee: ICAgen, Inc.Inventors: Grant A. McNaughton-Smith, Michael F. Gross, Alan D. Wickenden
-
Patent number: 6495550Abstract: The present invention provides a genus of pyridine-substituted benzanilides that are useful as openers of potassium ion channels. The compounds of the invention are of use in both therapeutic and diagnostic methods.Type: GrantFiled: February 2, 2001Date of Patent: December 17, 2002Assignee: ICAgen, Inc.Inventors: Grant McNaughton-Smith, Paul Christopher Fritch, George Salvatore Amato
-
Publication number: 20020091122Abstract: Benzanilides are provided which are voltage-dependent potassium channel openers. Methods of using the benzanilides of the invention are also provided.Type: ApplicationFiled: December 6, 2001Publication date: July 11, 2002Applicant: Icagen, Inc.Inventors: Grant A. McNaughton-Smith, Michael F. Gross, Alan D. Wickenden
-
Publication number: 20020052393Abstract: Benzanilides are provided which are voltage-dependent potassium channel openers. Methods of using the benzanilides of the invention are also provided.Type: ApplicationFiled: November 2, 2001Publication date: May 2, 2002Applicant: Icagen, Inc.Inventors: Grant A. McNaughton-Smith, Michael F. Gross, Alan D. Wickenden